G42 Healthcare, a Group 42 (G42) company, has announced the launch of its G42 Health AI Platform
The AI-powered, cloud-based solution, provides researchers, medical organisations and scientific institutes across the world with advanced tools to speed up the detection of COVID-19 in potentially infected patients as well as accelerate the discovery of a conclusive drug used for its treatment.
G42 Health AI Platform, available on G42 Cloud, provides its users with the following tools:
-Virus Genome Analysis Service: to rapidly identify virus genome and generate insights on the virus evolution and epidemiology.
-AI-Assisted CT Scan Evaluation: to rapidly quantify the signatures that are suggestive of COVID-19 and pneumonia.
-In Silico Drug Discovery Service: to shorten the drug screening time by enabling a wide range of computer simulations.
Peng Xiao, CEO of G42, said, “Technology plays a critical role in the battle against this pandemic. Through the G42 Health AI Platform, we hope to empower the research community and facilitate the discovery of breakthrough solutions that can effectively contribute to curbing the outbreak.”
